Drugs / SL-279252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03894618 | Mar 2019 → May 2023 | Hodgkins lymphoma, anal squamous cell carcinoma, cervical squamous cell carcinoma, diffuse large B-cell lymphoma +8 | Shattuck Labs, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-11-09 | Shattuck Labs, Inc. | Results Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights shattucklabs.com ↗
SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients |
| 2021-11-09 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252 shattucklabs.com ↗
For SL-279252 (PD1-Fc-OX40L), anti-tumor activity has been observed in heavily pretreated patients, including one confirmed partial response (PR), and a second unconfirmed PR, both in patients with PD-1/L1 inhibitor pretreated non-cutaneous melanoma. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-09 | Shattuck Labs, Inc. | Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights shattucklabs.com ↗ |
| 2021-11-09 | Shattuck Labs, Inc. | Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252 shattucklabs.com ↗ |
| 2021-10-01 | Shattuck Labs, Inc. | Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shattucklabs.com ↗ |
| 2021-08-11 | Shattuck Labs, Inc. | Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252 shattucklabs.com ↗ |
| 2019-05-06 | Shattuck Labs, Inc. | Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L) shattucklabs.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-279252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03894618 ↗ |
| Known as | PD1-Fc-OX40L | “The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human...” NCT03894618 ↗ |
| Action | Activate | “PD effects consistent with OX40 activation were observed” PMID 40042547 ↗ Mar 2025 |
| Modality | Protein / enzyme biologic | “fusion protein” NCT03894618 ↗ |
| Route | Intravenous | “SL-279252 was administered intravenously” PMID 40042547 ↗ Mar 2025 |